drugset / Trial / NCT01890629

Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)

NCT01890629

Phase 4 Completed 69 enrolled LG Life Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare efficacy and safety of initial combination therapy of Gemigliptin versus Sitagliptin or Glimepiride with Metformin on Glucose Variability(MAGE, Glucose SD) in Patients With Type 2 Diabetes Mellitus.

Timeline

Start
2013-05
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemigliptin Small molecule 50 mg
Subject Glimepiride Small molecule 2 mg
Subject Sitagliptin Small molecule 100 mg
Background Metformin Small molecule 500 mg
Background Metformin Small molecule 1000 mg